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Background and purpose: Multiple sclerosis (MS) patients are at increased infection
risk. Here the inﬂuences of susceptibility, severity and surveillance bias on infection-
related hospital admission are assessed.
Methods: Swedish registers identiﬁed 20 276 patients with MS, matched with
203 951 people from the general population without MS. Risk of ﬁrst hospital admis-
sion for infection and mortality over 36 years was estimated by Poisson regression.
Results: Multiple sclerosis was associated with an increased hospital admission risk
for all infections, with an adjusted relative risk (and 95% conﬁdence interval) of
4.26 (4.13–4.40). A proportion of this raised risk was probably due to surveillance
and referral bias, although a raised risk remained when MS was compared with
other immune-mediated diseases. The 1-month mortality rate following hospital
admission for infection was higher in MS patients than in the comparison cohort,
with a relative risk of 4.69 (4.21–5.22). There was no clear temporal trend in the
results, and risks were higher in males and varied by MS phenotype.
Conclusions: Higher hospital admission rates among MS patients for infection are
likely to be due to a combination of surveillance bias, cautious medical management
and greater susceptibility to severe infections. MS-related functional limitations may
increase infection risk and this should be considered in MS management.
Background and purpose
A raised risk of infections among multiple sclerosis
(MS) patients has potential implications for clinical
management and resource use and is a concern as
infections may increase the risk of MS relapses [1–5].
Also, immunotherapy in MS [6] may increase infec-
tion risk. Although a lower rate of common viral
infections has sometimes been reported in MS [7],
excess infection-related mortality has been well docu-
mented [8–11]. Previous studies examined hospital
admission and infections in MS patients [12,13]. This
Swedish register study extends earlier work by focus-
ing speciﬁcally on infection type and considers the
potential roles of susceptibility, surveillance bias and
referral patterns. Severity is investigated through
mortality risk following hospital admission. Variation
of admission risk by calendar period was used to
assess potential variations in exposures over time.
Associations with MS phenotype and sex were also
examined as some studies have found an excess male
mortality risk [14].
Methods
Subjects
Patients who received a diagnosis of MS in Sweden
between 1969 and 2005 were identiﬁed through two
complementary sources: the Patient Register and the
Multiple Sclerosis Register. The Patient Register has
recorded the main and secondary hospital discharge
diagnoses since 1964. Initially national coverage was
partial, with only 15 Swedish counties (from a total of
26) reporting to the register by 1970. Coverage
increased to 20 counties reporting by 1980 and full
national coverage was achieved by 1987 [15]. The
Swedish Multiple Sclerosis Register has recorded
information on patients with MS since 1996, although
the proportion of patients registered increased more
notably from 2001 [16,17]. The coverage of the Multi-
ple Sclerosis Register varies by county, and during the
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earlier period of its coverage it was more likely to
include patients receiving immunomodulatory therapy
[17]. Prevalent MS patients recorded in this register
are on average younger than those in the Patient Reg-
ister due to the relatively recent founding of the Mul-
tiple Sclerosis Register [17]. Both registers are used as
the Patient Register identiﬁes a large number of MS
patients diagnosed over several decades while the
Multiple Sclerosis Register identiﬁes a smaller number
of patients but with conﬁrmed high diagnostic accu-
racy.
A total of 20 543 individuals with a diagnosis of
MS were identiﬁed, including 7957 through the Multi-
ple Sclerosis Register. The Multiple Sclerosis Register
provided information on MS phenotype for the subset
of patients identiﬁed by this register. Phenotype was
deﬁned once at registration and is unavailable for a
proportion of patients (see Table 1) as phenotype
may be diﬃcult to assign for some at diagnosis. Link-
age between data sources was possible using the per-
sonal identity number issued to all Swedish residents
[18].
The design was that each patient with MS should
be individually matched with 10 Swedish residents
without an MS diagnosis, thus creating two cohorts.
Matching was performed by the government agency,
Statistics Sweden [19], using data from the Total Pop-
ulation Register which also provided dates of death
and emigration to deﬁne follow-up time. The match-
ing criteria, based on characteristics at the time of the
MS diagnosis, were county of residence in Sweden,
year of birth and sex. For each person with MS, indi-
viduals without MS who had the appropriate charac-
teristics for matching were identiﬁed, and from them
10 were selected at random. For a minority of subjects
with MS fewer than 10 MS-free subjects with the
Table 1 Characteristics of the MS and non-MS cohorts
Entire study population Subset from the Multiple Sclerosis Register
With MS (%) Without MS (%) With MS (%) Without MS (%)
Total 20 276 203 951 7958 89 102
Sex
Female 13 218 (65.2) 13 2638 (65.0) 5633 (70.8) 63 683 (71.5)
Age at MS diagnosis/entry (years)
<20 440 (2.2) 5828 (2.2) 323 (4.1) 3360 (3.8)
20–29 2836 (14.0) 28 640 (14.0) 1698 (21.3) 18 600 (20.9)
30–39 4412 (21.6) 44 056 (21.6) 2250 (28.3) 25 128 (28.2)
40–49 4762 (23.3) 47 309 (23.2) 2008 (25.2) 22 439 (25.2)
50 7826 (38.2) 78 118 (38.3) 1679 (21.1) 19 578 (22.0)
Mean (SD) 45.8 (15.5) 45.8 (15.6) 39.5 (12.2) 39.8 (12.4)
Age at ﬁnal follow-up (years)
<30 902 (4.5) 10 407 (5.1) 701 (8.8) 7615 (8.6)
30–39 2056 (10.1) 21 506 (10.5) 1625 (20.4) 17 766 (19.9)
40–49 3407 (16.8) 31 655 (15.5) 2087 (26.2) 22 522 (25.3)
50–59 4592 (22.7) 40 421 (19.8) 2075 (26.1) 22 916 (25.7)
60–69 4372 (21.6) 38 628 (18.9) 1110 (14.0) 13 318 (15.0)
70–79 3220 (15.9) 31 661 (15.5) 307 (3.9) 4150 (4.7)
>80 1727 (8.5) 29 673 (14.6) 53 (0.7) 815 (0.9)
Mean (SD) 55.2 (15.9) 57.9 (17.6) 46.8 (13.5) 47.2 (13.8)
Follow-up, years
<5 7103 (35.0) 50 981 (25.0) 3636 (45.7) 39 504 (44.3)
5–10 5441 (26.8) 49 453 (24.2) 2365 (29.7) 26 558 (29.8)
11–15 3609 (17.8) 37 123 (18.2) 873 (11.0) 10 134 (11.4)
>15 4390 (21.7) 66 608 (32.7) 1084 (13.6) 12 906 (14.5)
Mean (SD) 9.9 (8.3) 12.7 (9.6) 7.6 (7.3) 7.9 (7.6)
Calendar period
<1980 5264 (26.0) 52 599 (25.8) 486 (6.1) 6764 (7.6)
1980–1989 4912 (24.2) 48 372 (23.7) 983 (12.4) 11 038 (12.4)
1990–1999 5320 (2.6) 52 924 (25.9) 2666 (33.5) 29 398 (33.0)
2000–2005 5047 (24.9) 50 268 (24.6) 3182 (40.0) 35 134 (39.4)
MS phenotype
Primary progressive – – 601 (7.6) –
Progressive relapsing – – 66 (0.8) –
Relapsingremitting – – 3428 (43.1) –
Secondary progressive – – 2104 (26.4) –
No phenotype recorded – – 1759 (22.1) –
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same characteristics were available; where this
occurred all appropriate MS-free subjects were used.
A total of 204 163 people without MS were included
in the matched (non-MS) comparison cohort. We sub-
sequently excluded 267 people with MS and 212 with-
out MS due to missing information.
A six-category socioeconomic index (SEI) was con-
structed from census data, with categories for manual
workers, non-manual workers, professionals, self-
employment, farmers and others. The census used was
nearest in time to ﬁrst MS diagnosis in patients and
the same time-point for the individually matched
members of the non-MS cohort.
Hospital admissions
Inpatient infectious diagnoses between 1969 and 2005
were identiﬁed through the Patient Register using
ICD codes. During this period the version of ICD
varied both over time and by county, so the speciﬁc
codes used diﬀered by period and region. Infections
were identiﬁed using ICD-10 codes: A00-B99, G00-
G02, G06-G07, J00-J22, J32, J35-J37, M00-M01, L00-
L02, L08, H66, N10 and N300. The analysis examined
all infections combined, by organ system or speciﬁc
diagnosis, in the groups and diagnoses presented in
Table 2. The individual infections and grouped infec-
tions were chosen on an a priori basis and results for
all of these infections are presented, except for ﬁve.
We did not present results for infections that were too
rare, as the diagnostic accuracy for some rare condi-
tions can be unacceptably low in the Patient Register,
making the risk of producing spurious results far
greater. The criterion that we used to deﬁne rarity
was where fewer than 50 diagnoses of a speciﬁc infec-
tion were identiﬁed in each cohort. The infections that
were not presented due to rarity are viral pneumonia,
pneumocystis pneumonia, progressive multifocal leu-
coencephalopathy, infectious mononucleosis and Pseu-
domonas aeruginosa.
Multiple sclerosis is a chronic disease, usually
resulting in more frequent contact with health ser-
vices, and incidental diagnoses are more often
recorded than among the general population, which
can result in surveillance bias. To reduce potential sur-
veillance bias, infections were only included if they
were recorded as the primary hospital admission diag-
nosis and thus likely to be the main reason for hospi-
tal admission. Further analysis took into account the
number of all hospital admissions between the time of
ﬁrst MS diagnosis and outcome infection. This was
designed to indicate and adjust for the eﬀects of
chronic disease and related referral patterns. Addition-
ally, MS patients were compared with a subset of the
non-MS cohort comprising subjects with other
immune-mediated diseases. The smaller comparison
cohort (n = 13 731) included only those with a diag-
nosis of ulcerative colitis (n = 819), Crohn’s disease
(n = 669), psoriasis (n = 800), type 1 diabetes (8611),
rheumatoid arthritis (n = 2130), polyarteritis nodosa
(n = 45), temporal arteritis and polymyalgia rheumati-
ca (n = 1077), Addison’s disease (n = 112) or pem-
phigoid (n = 68). Individuals could have more than
one of these diagnoses.
Table 2 The risk of infection-related hospital admissions for MS patients
Events: MS cohort
(n = 20 276)
Events: non-MS
cohort (n = 203 951)
Unadjusted relative
risk (95% CI)
Adjusteda relative
risk (95% CI)
Adjustedb relative
risk (95% CI)
All infections 5167 19 148 3.64 (3.52–3.75) 4.26 (4.13–4.40) 2.36 (2.28–2.43)
Sex
Male 2178 7932 4.15 (3.95–4.35) 4.95 (4.72–5.20) 2.67 (2.54–2.81)
Female 298 11 216 3.37 (3.24–3.51) 3.86 (3.70–4.02) 2.15 (2.05–2.24)
Respiratory infections 3095 10 177 3.87 (3.71–4.03) 4.74 (4.55–4.94) 2.55 (2.44–2.66)
Inﬂuenza 284 564 6.06 (5.25–6.99) 7.23 (6.25–8.36) 3.57 (3.06–4.15)
Bacterial pneumonia 455 1126 4.99 (4.47–5.57) 6.13 (5.48–6.85) 2.73 (2.43–3.06)
Pneumonia in bacterial diseases 323 1214 3.17 (2.80–3.58) 3.83 (3.38–4.34) 1.96 (1.72–2.23)
Gastrointestinal infectious diseases 604 2312 3.09 (2.82–3.38) 3.39 (3.09–3.71) 1.59 (1.45–1.75)
Viral and other speciﬁed
gastrointestinal infections
174 670 3.06 (2.59–3.61) 3.45 (2.91–4.09) 1.46 (1.22–1.74)
Infections of the skin and
subcutaneous tissue
493 2064 2.84 (2.58–3.14) 3.16 (2.86–3.49) 1.51 (1.36–1.67)
Infectious arthropathies 76 487 1.85 (1.45–2.36) 2.10 (1.65–2.68) 0.98 (0.76–1.26)
Septicaemia 923 2198 5.13 (4.75–5.54) 6.20 (5.73–6.70) 2.89 (2.66–3.13)
Infections of the urinary system 1513 2571 7.23 (6.79–7.71) 8.22 (7.71–8.77) 4.08 (3.81–4.36)
aAdjusted for duration, sex, age at entry, period at entry, region and SEI.
bAdjusted for all of the above and total number of hospital admissions during the follow-up period.
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Mortality
Infectious causes of death were identiﬁed through the
Cause of Death Register [20] which uses information
recorded on death certiﬁcates. Despite low accuracy
for some diagnoses on death certiﬁcates, there is evi-
dence that infectious causes such as pneumonia and
inﬂuenza have a relatively high accuracy: a study con-
ﬁrmed an accuracy of 83% for these diagnoses [21].
The data received from this register were abbreviated
so that it was possible to identify infectious causes but
not more speciﬁc diagnoses. Although date of death
was available for the entire study period, causes of
death were only available for between 1969 and 1997.
Mortality during the 30 days following hospital
admission for infection among MS and non-MS
patients was assessed to determine risk of life-threat-
ening infection.
Statistical analysis
The main analyses compared the MS and non-MS
cohorts with follow-up time beginning at ﬁrst recorded
MS diagnosis (and the same time-point for the individ-
ually matched members of the comparison cohort) and
ending at the ﬁrst inpatient diagnosis of infection, emi-
gration, death or study end in 2005, whichever
occurred ﬁrst. Relative risk for the ﬁrst relevant infec-
tious event was estimated by Poisson regression with
adjustment for follow-up duration, year at entry and
age at entry (under 5 years, then in 5-year age groups
to 84 years and with a ﬁnal category for 85 years or
older), sex, county and SEI. Stratiﬁcation by period of
outcome infection was all infections grouped together
and also for one of the common infections, inﬂuenza.
Additional adjustment was for the total number of
admissions for any diagnosis between the dates of ﬁrst
MS diagnosis and infection or study exit. The above
analyses were repeated using a subset of the non-MS
cohort comprising only people with other immune-
mediated diseases.
The Multiple Sclerosis Register contains some infor-
mation not available from the Patent Register, includ-
ing MS phenotype. Also, the accuracy of an MS
diagnosis is more readily veriﬁable using the Multiple
Sclerosis Register [22]. Therefore, some analyses were
limited to the subset of MS patients identiﬁed in the
Multiple Sclerosis Register and the relevant matched
members of the non-MS cohort. Due to the reduction
in numbers, the analysis was limited to all infectious
diagnoses grouped as the outcome. MS patients were
compared with the non-MS cohort for each MS
phenotype separately and then the phenotypes were
compared only among the MS patients.
Analysis of infection-related mortality was per-
formed using Poisson regression for the period from
study entry to death, emigration or 1997, whichever
occurred ﬁrst. Adjustment was for duration, sex,
region, age at entry, period at entry and SEI. Similar
methods examined whether there was a raised risk of
all-cause mortality in the 30 days following hospital
admission for infection.
Ethics approval
This study was approved by the Karolinska Institutet
ethics committee.
Results
The characteristics of the cohorts are shown in
Table 1. The ﬁrst two columns describe the entire
study population (MS and non-MS cohorts) and the
second two columns are for the subset of MS patients
from the Multiple Sclerosis Register and members of
the non-MS cohort matched with them. As the MS
and non-MS cohorts were matched, there were no
notable diﬀerences in sex, age at study entry or calen-
dar period. Duration of follow-up and age at exit
tended to be greater for the non-MS cohort. Com-
pared with the entire study population, those from the
Multiple Sclerosis Register tended to be younger at
diagnosis, showed a higher proportion of women and
entered the study at a more recent calendar period.
The commonest MS phenotype was relapsing
remitting.
Infection-related hospital admissions
There was a statistically signiﬁcant association
between MS and hospital admission for any infection
before and after adjustment for potential confounding
factors (Table 2). The magnitude of association was
higher among men. After adjustment for the potential
confounding factors, except total number of admis-
sions for any cause, MS was statistically signiﬁcantly
associated with a raised risk for all infections and the
grouped and individual infections resulting in hospital
admission, with the highest risks observed for urinary
tract infections and inﬂuenza. The largest magnitude
sex diﬀerence was for urinary tract infections, with
adjusted relative risks (and 95% conﬁdence intervals)
of 13.87 (12.5–15.39) for males and 6.02 (5.53–6.55)
for females. There was also a sex diﬀerence for inﬂu-
enza, with adjusted relative risks of 9.93 (7.98–12.35)
for males and 5.69 (4.67–6.93) for females.
After additional adjustment for total number of
admissions, the magnitude of the associations between
© 2013 The Author(s)
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MS and infections was attenuated but remained raised
and statistically signiﬁcant, with the exception of
infectious arthropathies which showed no association
with MS (Table 2). Exclusion of events in the ﬁrst
5 years following ﬁrst recorded MS diagnosis yielded
statistically signiﬁcant and similar estimates (data not
shown), indicating that the results were not explained
by admissions that coincided with the ﬁrst MS diag-
nosis.
When MS patients were compared with subjects
who had another hospital-diagnosed immune-
mediated disease (Table 3), the associations of MS
with hospital admission for infections were attenuated
to a greater extent than those in Table 2. Statistically
signiﬁcant raised risks for infectious admissions
remained except for gastrointestinal infections, infec-
tious arthropathies and infections of the skin and sub-
cutaneous tissue. Statistically signiﬁcant inverse
associations with MS were observed for the last two
outcomes. Further adjustment for total number of all
hospital admissions did not alter any of the associa-
tions noticeably (data not shown).
Among the subset of MS patients identiﬁed through
the Multiple Sclerosis Register and their matched
non-MS cohort, MS was statistically signiﬁcantly
associated with a raised risk of hospital admission for
any infection diagnosis, with a higher magnitude asso-
ciation among males (Table 4). There was a statisti-
cally signiﬁcant raised risk of hospital admission for
infections for each of the four phenotypes, with the
highest risk for primary and secondary progressive
phenotypes. When comparisons were made between
MS patients, with the secondary progressive pheno-
type as reference, the only statistically signiﬁcant
Table 3 Infection-related hospital admissions among subjects with MS compared with a group of patients with other immune-mediated
diseasesa
Events: MS cohort
(n = 19 022)
Events: other immune-mediated
disease cohorta (n = 13 731)
Unadjusted RR
(95% CI)
Adjusted RRb
(95% CI)
All infections 4558 3616 1.82 (1.74–1.91) 1.78 (1.70–1.87)
Respiratory infections 2761 1947 2.13 (2.01–2.27) 2.05 (1.92–2.18)
Inﬂuenza 248 121 2.70 (2.14–3.40) 2.57 (2.03–3.25)
Bacterial pneumonia 401 192 3.13 (2.61–3.75) 2.01 (1.66–2.42)
Pneumonia in bacterial diseases 293 266 1.68 (1.41–2.00) 1.81 (1.51–2.16)
Gastrointestinal infectious diseases 509 528 1.11 (0.98–1.27) 0.99 (0.87–1.14)
Viral and other speciﬁed gastrointestinal infections 144 175 0.96 (0.76–1.22) 0.82 (0.64–1.04)
Infections of the skin and subcutaneous tissue 397 550 0.88 (0.77–1.01) 0.84 (0.73–0.96)
Infectious arthropathies 63 144 0.56 (0.41–0.77) 0.48 (0.35–0.66)
Septicaemia 783 615 1.88 (1.68–2.1) 1.60 (1.43–1.8)
Infection of urinary system 1312 530 3.38 (3.04–3.76) 3.18 (2.86–3.55)
aMembers of the comparison cohort have a diagnosis of ulcerative colitis (n = 819), Crohn’s disease (n = 669), psoriasis (n = 800), type 1
diabetes (8611), rheumatoid arthritis (n = 2130), polyarteritis nodosa (n = 45), temporal arteritis and polymyalgia rheumatica (n = 1077), Addi-
son’s disease (n = 112) or pemphigoid (n = 68).
bAdjusted for sex, area, duration, age at entry, period and SEI. Further adjustment for total number of hospital admissions did not change the
results.
Table 4 The risk of infection-related hospital admissions by MS phenotype
Events: Multiple Sclerosisb
Register cohort (n = 7958)
Events: non-MSb
cohort (n = 89 105)
Unadjusted relative
risk (95% CI)
Adjusteda relative
risk (95% CI)
All infections 992 3353 3.39 (3.16–3.64) 3.49 (3.25–3.74)
Sex
Male 388 1023 4.47 (3.98–5.03) 4.54 (4.03–5.11)
Female 604 2330 2.94 (2.69–3.22) 3.05 (2.79–3.33)
MS phenotype
Primary progressive 124 338 4.45 (3.61–5.47) 4.46 (3.62–5.50)
Progressive relapsing 8 37 2.79 (1.29–6.02) 2.64 (1.21–5.78)
Relapsing remitting 150 851 1.90 (1.60–2.27) 1.92 (1.60–2.92)
Secondary progressive 522 1562 3.97 (3.59–4.38) 4.02 (3.63–4.44)
aAdjusted for duration, sex, age at entry, period at entry, region and SEI.
bThese results are limited to the subset of patients identiﬁed through the Multiple Sclerosis Register and the relevant individually matched
members of the comparison cohort.
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diﬀerence after adjustment was with the relapsing
remitting phenotype which had a lower infection risk,
producing a relative risk of 0.39 (0.32–0.48).
Stratiﬁcation by calendar period (Table 5) found
non-conclusive evidence of a modest rise of infection
risk over the ﬁrst three periods but not in the fourth,
which was the least precisely estimated as the duration
was shorter.
Infection-related mortality
Multiple sclerosis patients were statistically signiﬁ-
cantly more likely to have infection-related mortality
(Table 6). The risk was higher for males and the rela-
tive risk for infection-related mortality associated with
MS was greatest at younger ages.
Mortality during the 30 days following hospital
admission for an infection involved 443 deaths among
the MS cohort and 1629 in the non-MS cohort, pro-
ducing an unadjusted relative risk of 4.60 (4.13–5.12).
Adjustment for the potential confounding factors,
except total number of admissions, increased the risk
to 4.69 (4.21–5.22), and further adjustment for total
number of admissions attenuated it somewhat to 4.18
(3.73–4.68). There were no notable sex diﬀerences
(data not shown).
Discussion
In this study patients with MS were admitted to hos-
pital for a range of infectious diseases signiﬁcantly
more often than matched members of the general pop-
ulation (the non-MS cohort). They were also more
likely to have died from infectious causes and to have
died during the month following a hospital admission
for infection.
Disease associations using hospital diagnoses are
potentially subject to inﬂation by surveillance bias,
particularly for chronic conditions involving frequent
contact with health services when incidental diagnoses
can be recorded. To tackle this, infectious outcomes
were limited to the primary diagnosis and thus the
most likely reason for hospital admission. To avoid
the results being driven by multiple admissions among
a subset of the study population, the analyses exam-
ined risk of first hospital admission for infections. To
further address surveillance bias, the total number of
admissions for any cause during the follow-up period
Table 5 Temporal variation in infection-related hospital admissions for MS patients
Events: MS cohort
(n = 20 276)
Events: non-MS
cohort (n = 203 951)
Unadjusted relative
risk (95% CI) Adjusteda relative risk (95% CI)
All infections
<1980 702 1726 3.49 (3.33–3.67) 4.14 (3.95–4.35)
1980–1989 1411 4743 3.54 (3.36–3.73) 4.29 (4.06–4.52)
1990–1999 1744 7438 4.03 (3.75–4.32) 4.40 (4.09–4.72)
2000–2005 1310 5241 4.11 (3.56–4.76) 4.25 (3.66–4.92)
Inﬂuenza
<1980 113 239 5.13 (4.13–6.38) 6.24 (5.00–7.79)
1980–1989 92 169 6.12 (4.74–7.89) 7.58 (5.85–9.83)
1990–1999 70 88 8.31 (6.07–11.38) 9.13 (6.64–12.55)
2000–2005 9 14 6.51 (2.82–15.05) 6.98 (3.01–16.17)
aAdjusted for duration, sex, age at entry, region and SEI.
Table 6 Infection-related mortality risk for MS patients
Events: MS cohort
(n = 20 276)
Events: non-MS cohort
(n = 203 951)
Unadjusted relative
risk (95% CI)
Adjusteda relative
risk (95% CI)
Infection-associated
mortality
1601 4808 3.97 (3.75–4.20) 5.19 (4.90–5.50)
Sex
Male 730 2221 4.21 (3.87–4.58) 5.60 (5.14–6.11)
Female 871 2587 3.84 (3.55–4.14) 4.86 (4.49–5.25)
Age at study exit (years)
<40 96 133 6.09 (4.66–7.97) 5.16 (3.92–6.80)
40–59 534 785 5.55 (4.97–6.20) 4.10 (3.66–4.59)
60–79 798 2206 4.06 (3.74–4.40) 3.41 (3.14–3.70)
80 173 1684 2.43 (2.08–2.84) 2.81 (2.40–3.30)
aAdjusted for duration, sex, age at entry, period at entry, region and SEI.
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was adjusted for, as a marker of frequency of contact
with health services. This adjustment reduced the
magnitude of association between MS and infections
but signiﬁcantly raised risks remained. Cautious man-
agement of MS patients could result in a form of
referral bias. Comparison of MS patients only with
subjects who had another immune-mediated disease
was undertaken to reduce the relative inﬂuence of sur-
veillance and referral bias further: this produced the
lowest magnitude estimates of association between
MS and hospital admission for infection, but they
remained statistically signiﬁcant. The diﬀerent meth-
ods to tackle surveillance and referral bias produced a
range of estimates, the highest indicating the high use
of inpatient health services by MS patients but
inﬂated by surveillance and referral bias, whilst the
lowest estimates show that a signiﬁcant association
persists even after more robust eﬀorts to eliminate the
eﬀect of these biases. The results are consistent both
with a higher risk of infection and greater likelihood
of hospital admission for infection.
Despite an overall positive association of MS with
hospital admission in comparison with the reduced
non-MS cohort of those with immune-mediated dis-
eases, a minority of the infection groups were inver-
sely associated with MS. This is likely to reﬂect higher
risk for some infection types associated with diseases
in the comparison cohort. Using several comparison
diseases allowed adequate statistical power and pro-
vided comparison with diseases imparting susceptibil-
ity to a wider range of infections.
There was a raised risk for infection-related mortal-
ity among MS patients. Relative risks for infection-
related mortality in MS were higher for younger age
groups. People with MS admitted to hospital with an
infection were signiﬁcantly more likely to have died
within a month compared with people without MS
also admitted to hospital for infections, indicating
greater average infectious disease severity among the
MS patients.
The lack of clear temporal patterns suggests that a
major part was not played by treatments such as
interferon beta, which can produce febrile symptoms
[23]. Interferon beta was introduced in Sweden for
MS in 1996 and its use increased over the subsequent
years [24]. Other MS treatments that may potentially
increase some types of infection risk include glatir-
amer acetate (Copaxone), which was licensed for use
in Sweden in 2001 but the agreement that costs for
this prescribed medication would be refunded took
eﬀect in July 2004. Thus glatiramer acetate could only
inﬂuence results noticeably during the last period of
our study. Vaccination programmes may be important
in controlling infection in this patient group. Guide-
lines to promote inﬂuenza vaccination in Sweden were
introduced in 1997 and the numbers vaccinated in the
general population began to increase noticeably from
2003. MS patients would be more likely to be vacci-
nated than the general population, and the greatest
coverage is likely to have been during the latter years
of our study period.
The risk of urinary tract and gastrointestinal infec-
tions may be raised by the bladder and bowel dys-
function experienced by MS patients [25–27], while an
inability to cough and clear the lungs [28] may
increase respiratory infection risk. It is unlikely that
MS patients have a life-long increased susceptibility to
infections prior to MS onset even though the pattern
of infections may be relevant for MS risk [29–31] as
frequency of childhood infections prior to MS onset is
not signiﬁcantly increased. The higher risk for infec-
tion-related hospital admission in men was unexpected
and the speculation is that, if not due to chance, it
may reﬂect greater MS severity or increased suscepti-
bility to infections. Immunizations may help to reduce
infection risk and are not generally associated with
increased MS relapse rates [32], although they may
not prevent all relevant infections.
Data from the Multiple Sclerosis Register were
available only for a subset of MS patients used in this
study, but provided useful complementary informa-
tion. The majority of MS diagnoses were identiﬁed
through the Patient Register, which despite acceptable
levels of diagnostic accuracy may contain a propor-
tion of misdiagnoses [15]. For this reason our main
ﬁndings were replicated using Multiple Sclerosis Reg-
ister patients to ensure that the results were not driven
by a poorly deﬁned patient population. There are
some diﬀerences in characteristics between patients
identiﬁed through the Multiple Sclerosis and Patient
Registers relevant to age, phenotype and treatment
[17], but we previously demonstrated that the Multiple
Sclerosis Register is accurate for over 95% of diagno-
ses [22].
Patients with MS are at a noticeably raised risk of
serious infections leading to hospital admission and
infection-related mortality, even at younger ages. A
component of the raised infection risk may be due to
MS-related functional limitations. There is no evi-
dence of substantial change in relevant environmental
exposures over time. These ﬁndings emphasize the
continuing importance of prevention strategies includ-
ing through urological care.
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